EDINBURGH - TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a biotechnology firm specializing in gamma-delta T cell therapies for cancer, has reported significant progress in its clinical trials and operational advancements in 2024. The company has successfully administered increased dosages of its cancer treatment TCB008 to patients in the ACHIEVE UK trial, following the Medicines and Healthcare products Regulatory Agency's (MHRA) approval of the dosing amendment. So far, eight patients have been dosed, with two receiving their fourth and final dose.
The expansion of the trial to new sites, including the prominent Guy's and St. Thomas Hospital in London, indicates growing interest in the therapy. The company is also planning to open additional trial sites in early 2025. Parallel to the clinical trials, TC BioPharm has initiated a compassionate use program in the UK and US, which has garnered physician interest for TCB008's application in various cancer forms.
Moreover, TC BioPharm has signed two non-binding letters of intent for acquisitions to broaden its cell therapy portfolio and announced a collaboration with a leading infectious disease expert in the UK to develop a treatment for Mpox. The company has also partnered with a university for an AI-driven donor screening initiative, targeting the allogeneic cell therapy market.
Financially, TC BioPharm has reduced its cash burn by 50% in Q1 2024 and secured an $8 million capital injection from an investor group in August. The company's strategic alignment of R&D towards commercial applications is showing tangible results, with anticipated manufacturing process improvements by Dr. Lauren Bor's team.
Looking forward, TC BioPharm aims to continue its strategic initiatives into 2025, focusing on data readouts for Cohort B, amending its Phase 1b FDA trial for a shorter timeline, and executing its acquisition strategy to enhance its cell therapy offerings.
This update is based on a press release statement issued by TC BioPharm. The company cautions that the forward-looking statements in the release involve risks and uncertainties that could cause actual results to differ materially from those projected. Investors are advised to consider these factors alongside the achievements and operational highlights disclosed.
In other recent news, TC BioPharm has been active in various developments. The company successfully raised $2 million through a direct offering of shares and warrants and secured an additional $3.9 million from the exercise of warrants, with H.C. Wainwright & Co. serving as the exclusive placement agent. In a significant move, TC BioPharm has also secured a European patent for its modified gamma-delta T cell therapies, aimed at treating cancer and viral indications.
The company has initiated preclinical studies for its therapeutic candidate, TCB 008, targeting the treatment of monkeypox, and reported progress in its ACHIEVE Phase 2b clinical trial. TC BioPharm also announced compliance with Nasdaq's Minimum Stockholders' Equity Requirement, ensuring its continued listing on the Nasdaq Global Select Market.
In addition, TC BioPharm has implemented a one-for-10 reverse American Depositary Shares (ADS) split, overseen by The Bank of New York Mellon (NYSE:BK). The company has publicly refuted rumors regarding its Nasdaq listing status, confirming that it remains fully compliant with all Nasdaq listing requirements and has no intention of delisting.
Lastly, TC BioPharm has expressed its intention to acquire a biotechnology firm specializing in Chimeric Antigen Receptor T-cell therapies for cancer treatment, subject to satisfactory negotiations, adequate financing, and necessary third-party approvals. These are the recent developments at TC BioPharm.
InvestingPro Insights
TC BioPharm's recent progress in clinical trials and operational advancements comes against a backdrop of significant financial challenges, as revealed by InvestingPro data. The company's market capitalization stands at a modest $0.89 million, reflecting investor caution despite the positive developments in its cancer treatment pipeline.
InvestingPro Tips highlight that TC BioPharm is "quickly burning through cash" and "may have trouble making interest payments on debt." These insights align with the company's reported efforts to reduce cash burn by 50% in Q1 2024 and secure additional funding. The recent $8 million capital injection from investors appears crucial given these financial pressures.
The stock's performance has been notably weak, with InvestingPro data showing a staggering 94.89% year-to-date price decline. This steep drop underscores the market's skepticism about the company's near-term prospects, despite the promising clinical trial results and expansion plans outlined in the article.
Investors considering TC BioPharm should note that InvestingPro lists 16 additional tips for this stock, offering a more comprehensive analysis of the company's financial health and market position. These insights could be particularly valuable given the volatility and risks associated with biotechnology investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.